[HTML][HTML] Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
L Zhong, Y Li, L **ong, W Wang, M Wu… - Signal transduction and …, 2021 - nature.com
Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …
Advances in acute myeloid leukemia
LF Newell, RJ Cook - Bmj, 2021 - bmj.com
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …
historically high mortality rates. The standard of care treatment remained unchanged for …
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
ST Diepstraten, MA Anderson, PE Czabotar… - Nature Reviews …, 2022 - nature.com
Apoptosis is a form of programmed cell death that is regulated by the balance between
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
AH Wei, P Montesinos, V Ivanov… - Blood, The Journal …, 2020 - ashpublications.org
Effective treatment options are limited for patients with acute myeloid leukemia (AML) who
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized …
WG Wierda, JN Allan, T Siddiqi, TJ Kipps… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal
residual disease (MRD)-guided treatment discontinuation following completion of first-line …
residual disease (MRD)-guided treatment discontinuation following completion of first-line …
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged≤ 70 years
with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort …
with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort …
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
U Jäger, W Barcellini, CM Broome, MA Gertz, A Hill… - Blood reviews, 2020 - Elsevier
Autoimmune hemolytic anemias (AIHAs) are rare and heterogeneous disorders
characterized by the destruction of red blood cells through warm or cold antibodies. There is …
characterized by the destruction of red blood cells through warm or cold antibodies. There is …
Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study
AH Wei, SA Strickland Jr, JZ Hou, W Fiedler… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Effective treatment options are limited for patients with acute myeloid leukemia
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
Abstract The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab
Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory …
Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory …